QH103 Cell is named as an intervention in 2 current clinical trials in our China register. None are recruiting at the moment. All registered phases are Phase 1. The sponsor with the most trials is Fujian Medical University (1). The most-studied condition is Relapsed/Refractory CD19-positive B-ALL.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Clinical Study of Universal CD19 CAR-γδT Cell Injection in the Treatment of Adult Relapsed/Refractory B-cell Lymphoma
NCT07367685 · ClinicalTrials.gov ↗ · Recurrent/Refractory B-cell Lymphoma
|
Phase 1 | Not yet open | The Second Affiliated Hospital of Fujian Medical University | China |
|
Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Leukemia
NCT07491263 · ClinicalTrials.gov ↗ · Relapsed/Refractory CD19-positive B-ALL
|
Phase 1 | Not yet open | Fujian Medical University | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Fujian Medical University | 1 |
| The Second Affiliated Hospital of Fujian Medical University | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 0 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China register name QH103 Cell (also registered as CD19CAR-γδT cell) as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 2 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Fujian Medical University (1) and The Second Affiliated Hospital of Fujian Medical University (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how QH103 Cell works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how QH103 Cell works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists QH103 Cell (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.